surface plasmon resonance (spr) based instrument biacore t200  (Biacore)

Journal: International Journal of Molecular Sciences

Article Title: Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain

doi: 10.3390/ijms25031593

Figure Lengend Snippet: Affinity analysis of the designed antibodies. ( A ) Initial affinity screening of designed antibodies binding to Aβ1-42 oligomers and AL fibrils, respectively, by ELISA. For each experiment, control group using PBS incubated with Aβ1-42 oligomers or AL fibrils was carried out. Experiments were performed three times, and each sample was run in triplicate. Data are expressed as mean ± SEM. M1–M30: different designed mutants; wild-type: crenezumab; control: PBS. ( B ) SPR profile of a direct comparison of wild-type (WT) and mutant (M5) binding to Aβ42 oligomers and AL fibrils using the Biacore T200. ( C ) Further affinity analysis of M5, M10, and M29 mutants binding to Aβ1-42 oligomers and AL fibrils, respectively, by Biacore T200.

Article Snippet: Based on the ELISA assay results, eight engineered antibodies were screening out for further binding affinity verification using a surface plasmon resonance (SPR)-based assay on Biacore T200 instruments.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Incubation, Comparison, Mutagenesis